Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype

Mariana Brandão, Samantha Morais, Luísa Lopes-Conceição, Filipa Fontes, Natália Araújo, Teresa Dias, Deolinda Pereira, Marina Borges, Susana Pereira, Nuno Lunet

ABSTRACT
Background: The cost of breast cancer care rises with higher stage at diagnosis; however, there are no real-world data regarding the cost of care according to breast cancer subtypes. This study aimed to estimate direct medical costs for early breast cancer care in the first 3 years after diagnosis according to subtype and stage, using patient-level data.

Methods: Women with newly diagnosed stage I–III breast cancer, admitted in 2012 to a Portuguese cancer centre were prospectively followed within the NEON-BC cohort. The use of health resources was obtained from each patient’s clinical and administrative records and costs were computed. Tumours were classified into the classic subtypes (hormone receptor-positive (HR+)/HER2−; HER2-positive (HER2+)); triple-negative breast cancer (TNBC)) and surrogate intrinsic subtypes (luminal A-like; luminal B-like; HER2 enriched; basal like).

Results: A total of 703 patients were included: 48.9% had stage I, 35.8% stage II and 15.2% stage III breast cancer; 76.4% had HR+/HER2−, 15.9% HER2+ and 7.7% TNBC. Median cost of care was €9215/patient in stage I, €13 019/patient in stage II and €15 011/patient in stage III and €10 540/patient in HR+/HER2−, €11 224/patient in TNBC and €41 513/patient in HER2+ breast cancer. Systemic therapy accounted for 69.2% of the cost of care among patients with HER2+, 12.0% among HR+/HER2− and 7.5% among TNBC patients. Similar differences were observed across surrogate intrinsic subtypes.

Conclusions: The cost of early breast cancer care was mainly driven by the tumour subtype and, to a lesser extent, by stage. The median cost of care was fourfold higher among patients with HER2+ tumours compared with those with hormone receptor-positive/HER2-negative and triple-negative breast cancer. This difference was mainly attributed to adjuvant treatment with trastuzumab.

INTRODUCTION
In developed countries, breast cancer is the most incident cancer and its standardised mortality rates have been decreasing over the last decades. This decline has been attributed to both an increasing frequency of early diagnosis and access to more efficient and targeted systemic treatments, besides improved radiotherapy and surgery. At the same time, the cost of each patient’s cancer care increased, due to new treatments, but also to the development of new technologies, such as imaging.

There are several studies estimating the cost of breast cancer care according to stage, showing that it increases from stages 0 to IV. Nevertheless, it is widely recognised that...
breast cancer is a group of molecularly distinct neoplasms, thus, drug regimens are now tailored not only to stage, but also to the tumour molecular subtype. This may have also led to rising costs, due to an increased use of targeted drugs, such as anti-HER2 treatments (eg, trastuzumab). Although health resource use may be expected to differ according to tumour subtype, there are other factors, such as number of affected lymph nodes, histological grade and medical history, that affect treatment decisions. Hence, the individual cost of cancer care can differ between patients with tumours of the same subtype, even within the same hospital. Nonetheless, there are no real-world data regarding cost of early breast cancer treatment according to the different tumour subtypes. This information is paramount to economic evaluations of innovative therapies, to provide evidence for reimbursement schemes and to substantiate healthcare policies. This is particularly important as the sustainability of healthcare systems is now being debated, and especially of cancer care.

In the European Union, in 2009, breast cancer represented the second highest economic cost (€15.0 billion, 12% of overall cancer costs) and accounted for the highest cancer-related healthcare costs (€6.7 billion; 13% of all cancer-related healthcare costs). In the USA, estimates of lifetime per-patient costs of breast cancer in 2009 ranged from US$20 000 to US$100 000, corresponding to 43%–212% of the US gross domestic product per capita at that time. Data from low-income and middle-income countries is scarcer, but some economic studies have also shown an increased cost of breast cancer care with rising stage.

Therefore, the aim of the present study was to estimate all direct medical costs regarding diagnosis and treatment of patients with early breast cancer for the first 3 years after diagnosis according to tumour subtype and stage, using patient-level data.

**METHODS**

**Setting**

The Portuguese Institute of Oncology of Porto (IPO-Porto) is the largest cancer-dedicated hospital in Portugal, admitting patients from any part of the country, but especially from the Northern region. IPO-Porto admits over 1000 new breast cancer cases/year in its Breast Clinic and covers the entire breast cancer continuum, from diagnosis to treatment (surgery, radiotherapy, systemic therapy and supportive care) and follow-up. All patients are discussed at a multidisciplinary tumour board and treatment is usually decided according to the European Society for Medical Oncology guidelines. After concluding surgery, radiotherapy and/or chemotherapy, patients with early breast cancer enter a follow-up phase, in which they have a medical consultation every 3 months until the end of the third year of follow-up and then every 6 months.

**Study design and participants**

Patients with newly diagnosed breast cancer, admitted to the Breast Clinic of IPO-Porto in 2012 were included in the “NEON-BC - Neuro-oncological complications of breast cancer” prospective observational cohort. Patients were eligible if they were 18 years or older, with histologically confirmed breast cancer, proposed for surgery and expected to be followed at IPO-Porto. In 2012, participants were excluded if they had a previous primary cancer treated with chemotherapy and/or axillary/thoracic radiotherapy; received breast surgery outside IPO-Porto; had a Montreal Cognitive Assessment score below 17 (or below 16 for women over 65 years old); were illiterate had a major psychiatric illness (eg, bipolar disorder, schizophrenia, among others); or due to other reasons (eg, previous breast surgery for benign conditions). However, at the third and fifth year of follow-up, 272 patients initially excluded from the cohort due to the above-mentioned reasons were invited to join the study and thus 240 additional patients were included (online supplemental figure 1). Women with stage 0 (in situ carcinoma) or stage IV breast cancer, and those without tumour biomarkers’ assessment were excluded from the present analysis.

**Data collection**

Patients’ sociodemographic characteristics were collected through face-to-face interviews using a structured questionnaire. Tumour characteristics, including stage, grade and biomarkers’ assessment were retrieved from clinical records. The occurrence of a previous primary cancer was collected through face-to-face interviews and from clinical records.

Staging was defined by the AJCC TNM seventh edition classification. Histological grade was classified from grade 1 (well differentiated) to grade 3 (poorly differentiated). Expression of hormone receptors (HR; oestrogen receptor (ER) and progesterone receptor (PgR)), over-expression/amplification of HER2 and Ki67 score were assessed by immunohistochemistry on the primary tumour, as described in the literature. When the immunohistochemistry score was 2+ (HER2-equivocal), fluorescence in situ hybridisation was performed. HRs were considered positive when their expression was ≥1%. Tumours were grouped according to the ‘classic’ classification into HR-positive/HER2-negative (HR+/HER2−); HER2-positive (HER2+); and triple-negative breast cancer (TNBC; HR-negative/HER2-negative). Tumours were also classified into surrogate intrinsic subtypes, using the 2011 St. Gallen Consensus guidelines: luminal A-like (ER-positive/PgR-positive/HER2-negative and Ki67 <15% (or grade 1, in cases in which Ki67 was not available)); luminal B-like (ER-positive, HER2-negative and either PgR positivity <20% or Ki67 ≥15% (or grade 3); or ER-positive and HER2-positive); HER2 enriched (HR-negative/HER2-positive); and basal like (HR-negative/HER2-negative).
Healthcare use during the first 3 years following breast cancer diagnosis was obtained from clinical and administrative records of each participant, namely: surgery (ie, breast and axillary); systemic treatment (ie, chemotherapy, hormone therapy and targeted therapy); radiation (ie, external radiotherapy and brachytherapy); appointments (ie, medical outpatient visits and nursing, psychology and social services appointments); hospitalisations; imaging; and laboratory and pathology examinations (including genetic testing). As IPO-Porto is a dedicated cancer centre, all patients’ healthcare use within the hospital was considered to be related with their breast cancer diagnosis. This information was used to compute the cost of each component of treatment and follow-up for each patient. The unit cost of drugs were provided by the Management and Planning Service of IPO-Porto and all other costs were retrieved from the 2015 Price Tables of the Portuguese National Health Service (NHS). When patients received breast cancer surgery, chemotherapy or targeted therapy before being admitted at IPO-Porto, the cost of those procedures was imputed based on the median cost of the same procedures at IPO-Porto. All costs were reported in euros at constant 2015 prices.

Information on relapse, diagnosis of a second primary cancer or death by any cause during the first 3 years after diagnosis was obtained from clinical records. Costs related to disease relapse or to a second primary cancer were integrated in this analysis.

Statistical analysis
Patients’ characteristics are presented as counts and proportions for all categorical variables, and median and percentiles 25 and 75 (P25–P75) for continuous variables. For statistical analysis, patients were stratified by classic tumour subtype. Adjusted ORs (aORs) and 95% CIs were computed using multinomial logistic regression to quantify the association between tumour subtype and healthcare use and costs from diagnosis to the third year of follow-up (dependent variable). Models were adjusted for age (continuous variable), education (54, 5–9, ≥10 years) and stage (I, II, III). Additionally, analyses were performed according to the surrogate intrinsic subtypes. The median cost of overall care per patient according to stage (I vs II vs III) was also assessed. All analyses were performed using STATA V.15 (StataCorp). All tests were two sided and a p<0.05 was considered significant.

RESULTS
Patients’ characteristics
Among the 703 patients, 48.9% presented with stage I, 35.8% with stage II and 15.2% with stage III; 76.4% had a HR+/HER2- tumour, 15.9% presented with HER2+ and 7.7% with TNBC (online supplemental figure 1, table 1). Patients with TNBC were younger, and patients with HER2+ and TNBC tumours were more frequently diagnosed at a later stage — proportion of patients with stage III: 20.5% and 20.4% among HER2+ and TNBC, respectively, vs 13.6% among HR+/HER2-. Other sociodemographic characteristics were similar among the three subgroups, as well as history of a previous cancer diagnosis. During the first 3 years of follow-up, there were 18 patients (out of 617; 2.9%) with disease relapse, 12 (out of 656; 1.8%) with a second primary cancer and 12 (out of 703; 1.7%) patients had died.

Healthcare use
When adjusting for age, education and stage at diagnosis, there were no differences in the type of breast or axillary surgery across the three classic subtype subgroups (table 2). Patients with HER2+ (aOR 27.09; 95% CI 9.79 to 74.98) and TNBC (aOR 2.74; 95% CI 1.08 to 6.97) were more likely to receive chemotherapy, compared with patients with HR+/HER2- tumours. Almost all patients with HR+/HER2– tumours received hormone therapy (99.8%) and 93.8% of HER2+ patients received targeted systemic therapy (trastuzumab). Overall, 74.1% of patients received adjuvant radiotherapy, with no significant differences between subgroups.

Healthcare costs
The median (P25–P75) overall cost of care per patient during the first 3 years after diagnosis was €11 516 (€7890–€16 376). The median cost of care was €9215 (€7268–€13 117)/patient for stage I, €13 019 (€10 075–€19 194)/patient for stage II and €15 011 (€11 469–€22 530)/patient for stage III (figure 1).

The median (P25–P75) overall cost was €10 540 (€7480–€13 611)/patient among patients with HER2+ (€9215 (€7268–€13 117)/patient among stage I, (€13 019 (€10 075–€19 194)/patient for stage II and (€15 011 (€11 469–€22 530)/patient for stage III (figure 1). The discrepancy between patients with HER2+ vs HR+/HER2– and TNBC was mainly driven by the cost of trastuzumab (median €29 006/patient). There was also a higher cost associated with chemotherapy and day hospital use among patients with HER2+ (median of €386 and €2164/patient, respectively) and TNBC (€398 and €390/patient) compared with those with HR+/HER2– tumours (€98 and €394/patient). HER2+ patients also had a higher cost associated with surgeries, appointments, imaging and other medical expenses than the HR+/HER2– subgroup. Patients with TNBC had a significantly higher cost associated with other medical expenses than HR+/HER2– patients. Overall, expenses associated with systemic therapy constituted 69.2% of the median cost of care of HER2+ patients, while they contributed to 12.0% and 7.5% among HR+/HER2– and TNBC patients, respectively (figure 2). In the HR+/HER2– and TNBC subgroups, surgery accounted for around 25% of the total cost, similar to radiotherapy (20% of total cost).

The cost of care by year after cancer diagnosis dropped abruptly from the first to the second and third years for patients with HR+/HER2– and TNBC (figure 1). However, among patients with HER2+ tumours, the cost was €9347/patient during the second year due to adjuvant trastuzumab treatment.
When combining the cost of care per subtype and stage, although patients with stage II and III had a higher median cost of care/patient versus those with stage I, these differences were small within each subtype—among HR+/HER2− patients, the cost ranged from €8498/patient (stage I) to €13 332/patient (stage III); in the HER2+ subgroup, it ranged from €38 216/patient (stage I) to €41 564/patient (stage III). Likewise, among patients with TNBC, the median cost was €9566/patient in stage I and €14 645/patient in stage III (online supplemental figure 2).

**Surrogate intrinsic subtypes analyses**

When categorising tumours according to the surrogate intrinsic subtypes classification, there were 87 patients with HR+/HER2− tumours, for whom it was not possible to discriminate between luminal A-like and luminal B-like, due to absence of information regarding PgR, Ki67 and/or histological grade. Among the 616 patients with available surrogate intrinsic subtype information, 33.1% had luminal A-like tumours, 52.9% had luminal B-like tumours (of which 246 were HER2− and 80 HER2+), 5.2% had HER2-enriched and 8.8%...
### Table 2: Association between breast cancer classic subtype and healthcare use in the first 3 years following a breast cancer diagnosis in 2012

|                          | HR+/HER2− (N=537) | HER2+ (N=112) | TNBC (N=54) |
|--------------------------|-------------------|---------------|-------------|
|                          | N (%)             | aOR (95% CI)* | aOR (95% CI)† | N (%) | aOR (95% CI)* | aOR (95% CI)† |
| **Surgery**              |                   |               |             |       |               |               |
| Breast surgery‡          |                   |               |             |       |               |               |
| Total mastectomy (vs breast-conserving surgery) | 241 (51.2) | 1.66 (1.04 to 2.67) | 1.41 (0.85 to 2.35) | 25 (51.0) | 1.18 (0.64 to 2.18) | 0.84 (0.43 to 1.64) |
| Axillary surgery§        |                   |               |             |       |               |               |
| Axillary dissection (vs none or sentinel lymph node biopsy) | 154 (33.3) | 1.74 (1.08 to 2.78) | 1.32 (0.67 to 2.61) | 19 (39.6) | 1.30 (0.69 to 2.44) | 0.51 (0.21 to 1.24) |
| Other surgeries/interventions ≥4 vs <4¶   | 181 (33.7) | 6.40 (3.83 to 10.69) | 6.60 (3.81 to 11.43) | 34 (63.0) | 3.01 (1.60 to 5.67) | 2.43 (1.24 to 4.74) |
| **Systemic therapy**     |                   |               |             |       |               |               |
| Any chemotherapy (yes vs no) | 286 (53.3) | 17.58 (6.87 to 44.97) | 27.09 (9.79 to 74.98) | 44 (81.5) | 3.70 (1.64 to 8.36) | 2.74 (1.08 to 6.97) |
| Timing of chemotherapy   |                   |               |             |       |               |               |
| Adjuvant (vs neoadjuvant)| 260 (91.9) | 0.70 (0.32 to 1.56) | 0.56 (0.22 to 1.41) | 38 (86.4) | 0.53 (0.20 to 1.41) | 0.49 (0.16 to 1.52) |
| Chemotherapy scheme      |                   |               |             |       |               |               |
| Anthracycline-based (yes vs no)** | 283 (99.0) | 0.21 (0.05 to 0.90) | 0.18 (0.04 to 0.82) | 43 (97.7) | 0.48 (0.05 to 4.95) | 0.50 (0.05 to 5.45) |
| Hormone therapy (yes vs no)†† | 536 (99.8) | 0.58 (0.31 to 1.08) | 0.71 (0.37 to 1.36) | 8 (18.2) | 0.52 (0.22 to 1.22) | 0.67 (0.27 to 1.61) |
| Targeted therapy (yes vs no)‡‡  | 0 (0.0) | -- | -- | 0 (0.0) | -- | -- |
| **Other treatments**     |                   |               |             |       |               |               |
| Radiotherapy (yes vs no) | 395 (73.6) | 0.85 (0.52 to 1.40) | 0.72 (0.43 to 1.22) | 44 (81.5) | 1.47 (0.68 to 3.16) | 1.19 (0.54 to 2.65) |
| Brachytherapy (yes vs no)§§ | 110 (27.8) | 0.58 (0.31 to 1.08) | 0.71 (0.37 to 1.36) | 8 (18.2) | 0.52 (0.22 to 1.22) | 0.67 (0.27 to 1.61) |
| **Other healthcare use¶¶††** |                   |               |             |       |               |               |
| Appointments ≥55 vs <55*** | 132 (24.6) | 1.77 (1.12 to 2.80) | 1.55 (0.96 to 2.52) | 19 (35.2) | 1.54 (0.81 to 2.90) | 1.27 (0.65 to 2.46) |
| Hospitalisations ≥2 vs <2††† | 209 (38.9) | 0.93 (0.601.45) | 0.97 (0.62 to 1.51) | 19 (35.2) | 0.86 (0.46 to 1.57) | 0.90 (0.49 to 1.66) |
| Genetic testing (yes vs no)‡‡‡ | 63 (11.7) | 0.60 (0.29 to 1.27) | 0.63 (0.27 to 1.34) | 9 (16.7) | 0.90 (0.37 to 2.23) | 0.94 (0.38 to 2.34) |

Continued...
|                      | HR+/HER2− (N=537) | HER2+ (N=112) | TNBC (N=54) |
|----------------------|-------------------|---------------|-------------|
| N (%)                | N (%)            | aOR (95% CI)* | aOR (95% CI)† | N (%) | aOR (95% CI)† | aOR (95% CI)† |
| The total may not add to 703 due to missing data. May not sum to 100% due to rounding. | Further adjusted for stage (I–III). | Patients who had breast-conserving surgery followed by total mastectomy are included in the total mastectomy group. Information regarding the type of breast surgery is not available for 84 patients who underwent surgery outside IPO-Porto. | Patients who had sentinel lymph node biopsy followed by axillary lymph node dissection are included in the axillary dissection group. One patient did not receive any type of axillary surgery (included in the HR+/HER2− subgroup). Information regarding the type of axillary surgery is not available for 84 patients who underwent surgery outside IPO-Porto. | Patients who had breast-conserving surgery followed by total mastectomy are included in the total mastectomy group. Information regarding the type of breast surgery is not available for 84 patients who underwent surgery outside IPO-Porto. | Patients who had sentinel lymph node biopsy followed by axillary lymph node dissection are included in the axillary dissection group. One patient did not receive any type of axillary surgery (included in the HR+/HER2− subgroup). Information regarding the type of axillary surgery is not available for 84 patients who underwent surgery outside IPO-Porto. |

*Adjusted for age (continuous) and education (<4, 5–9, ≥10 years).
†Further adjusted for stage (I–III).
‡Patients who had breast-conserving surgery followed by total mastectomy are included in the total mastectomy group. Information regarding the type of breast surgery is not available for 84 patients who underwent surgery outside IPO-Porto.
§Patients who had sentinel lymph node biopsy followed by axillary lymph node dissection are included in the axillary dissection group. One patient did not receive any type of axillary surgery (included in the HR+/HER2− subgroup). Information regarding the type of axillary surgery is not available for 84 patients who underwent surgery outside IPO-Porto.
¶Other surgeries/interventions include breast reconstruction surgeries, central venous catheter placement/removal and other ambulatory surgeries/interventions. The cut-off used was determined as percentile 75 of the number of other surgeries/interventions among the HR+/HER2− subgroup.
**Anthracycline-based chemotherapy includes: AC regimen: four or six cycles of concomitant doxorubicin (60 mg/m²) and cyclophosphamide (600 mg/m²); FEC regimen: six cycles of concomitant 5-FU (500 mg/m²), epirubicin (100 mg/m²) and cyclophosphamide (500 mg/m²); AC-T regimen: four cycles of concomitant doxorubicin (60 mg/m²) and cyclophosphamide (600 mg/m²), followed by four cycles of docetaxel (100 mg/m²); AC-paclitaxel regimen: four cycles of concomitant doxorubicin (60 mg/m²) and cyclophosphamide (600 mg/m²), followed by four cycles of paclitaxel (80 mg/m²); FEC-D regimen: three cycles of concomitant 5-FU (500 mg/m²), epirubicin (100 mg/m²) and cyclophosphamide (500 mg/m²), followed by three cycles of docetaxel (100 mg/m²).
††Among HR+/HER2+: 71 patients (13.2%) only received tamoxifen; 116 (21.6%) only received aromatase inhibitors; 104 (19.4%) received both tamoxifen and aromatase inhibitors; 90 (16.8%) received tamoxifen and/or aromatase inhibitors, plus goserelin (for ovarian function suppression during adjuvant treatment) or fulvestrant (for relapsed disease); 155 (28.9%) unknown. Among HER2+: 9 (11.2%) only received tamoxifen; 24 (30.0%) only received aromatase inhibitors; 10 (12.5%) received both tamoxifen and aromatase inhibitors; 18 (22.5%) received tamoxifen and/or aromatase inhibitors, plus goserelin (for ovarian function suppression during adjuvant treatment) or fulvestrant (for relapsed disease); 19 (23.8%) unknown.
‡‡Targeted therapy includes trastuzumab. Seven patients with HER2+ breast cancer did not receive trastuzumab due to: age >80 years (n=2), cardiovascular disease (n=3), T1a tumour (n=1), refusal (n=1).
§§Among those who received radiotherapy (n=521).
¶¶Does not include the number of laboratory and pathology tests, and imaging examinations, for which only the total cost per patient was available (included in table 3).
***Appointments: number of outpatient visits (surgery, medical oncology and radiation oncology, among others), and nursing, psychology and social services appointments. The cut-off used was determined as percentile 75 of the number of appointments among the HR+/HER2− subgroup.
†††The cut-off used was determined as percentile 75 of the number of hospitalisations among the HR+/HER2− subgroup.
‡‡‡Genetic testing includes: BRCA1 mutations and BRCA2 mutations (hereditary breast and ovarian cancer syndrome); deletions in MLH1 (hereditary nonpolyposis colon cancer); and TP53 mutations (Li-Fraumeni syndrome).

aOR, adjusted OR; HR, hormone receptors; IPO-Porto, Portuguese Institute of Oncology of Porto; TNBC, triple negative breast cancer.
had basal-like tumours. Patients with luminal B-like, HER2-enriched and basal-like tumours were diagnosed at a more advanced stage compared with luminal A-like patients (online supplemental table 1). Only 16.2% of luminal A-like patients received chemotherapy vs 76.4% of luminal B-like, 100% of HER2-enriched and 81.5% of basal-like patients (online supplemental table 2). Patients with luminal A-like tumours also had a lower number of appointments than the other subgroups.

The median overall cost of care during the first 3 years after diagnosis was €8232 (€6391–€10 931)/patient among luminal A-like, €12 493 (€8723–€22 237)/patient among luminal B-like, €38 297 (€34 510–€42 529)/patient among HER2-enriched and €11 224 (€9158–€14 645)/patient among the basal-like subgroup (online supplemental table 3 and online supplemental figure 3). Similar to that described for classic subtypes above, the higher treatment cost among patients with HER2-enriched tumours was mainly driven by the cost of trastuzumab. Among luminal B-like patients, 73 (22.4%) also received trastuzumab (as they had HER2+ tumours), which also partly explains the higher median cost of care of luminal B-like vs luminal A-like patients. The other reason is the higher spending related to chemotherapy and day hospital use among luminal B-like (median of €255 and €590/patient) vs luminal A-like patients (median of €0/patient, as 84.0% did not receive chemotherapy). Overall, systemic therapy accounted for 9.0% of the total median cost of care of luminal A-like patients, while it accounted for 45.6% among luminal B-like and 69.6% among HER2-enriched patients (online supplemental figure 4). Among patients with HER2-enriched tumours, treatment cost was stable across the different stages at diagnosis, due to the fact that they all received trastuzumab. Conversely, there was an increase in treatment cost from stage I to stage III among patients with the other three subtypes, especially among the luminal A-like subgroup (online supplemental figure 5).

DISCUSSION

To the best of our knowledge, this is the first study to estimate all direct medical costs among patients with early breast cancer according to tumour subtype. We found that the median overall cost of care during the first 3 years after breast cancer diagnosis was fourfold higher among patients with HER2+ tumours than HR+/HER2− or TNBC patients, and that this was primarily driven by the cost of adjuvant trastuzumab treatment. This cost relates not only to the trastuzumab price itself, but also to all other expenditures related to its administration and toxicity monitoring, that is, daily hospital use, appointments and medical tests (including cardiac imaging).

We have also shown that, among patients with HR+/HER2− and TNBC, the cost of breast cancer care was mainly driven by surgery and radiotherapy rather than by systemic therapy (chemotherapy and/or hormone therapy). Similar results were observed when comparing cost of care according to patients’ surrogate intrinsic subtype.

Additionally, we found that there is an increase in the total median cost of care from stage I (€9215/patient) to stage III (€15 011/patient). This is in line with a previous study from Portugal, conducted at IPO-Lisbon (a similar, dedicated cancer centre) in 2014, assessing costs within the first 2 years after breast cancer diagnosis. The authors estimated the mean cost to be €6094/patient in stage I, €9785/patient in stage II and €11 893/patient in stage III.28 These figures are similar to those reported in other European countries with an NHS, such as Italy,29 France30 and the UK.31 Yet interestingly, the cost discrepancies by stage are negligible when compared with the differences observed according to breast cancer subtypes. This is primarily explained by the fact that, in breast cancer, the intensity and type of treatment is driven not only by stage, but mostly by biology: most patients with TNBC and HER2+ tumours have indication to receive chemotherapy and anti-HER2 therapy (in the case of HER2+). Likewise, all patients with HR+ tumours should receive hormone therapy, regardless of stage.16 Concerning locoregional therapy, most
| HR+/HER2− (N=537) | N (%) | aOR (95% CI)* | aOR (95% CI)† | HER2+ (N=112) | N (%) | aOR (95% CI)* | aOR (95% CI)† | TNBC (N=54) | N (%) | aOR (95% CI)* | aOR (95% CI)† |
|-------------------|--------|---------------|---------------|---------------|--------|---------------|---------------|---------------|--------|---------------|---------------|
| **Surgery‡§**     |        |               |               |               |        |               |               |               |        |               |               |
| Surgeries, euros  |        |               |               |               |        |               |               |               |        |               |               |
| Median (P25-P75)  | 2522.01 | (1434.07–2880.94) | 2684.49 | (2511.01–3939.67) | 2522.01 | (2094.72–3654.94) |               |               |        |               |               |
| ≤1800¶           | 179    | (33.9)        | 10           | (8.9)        | 9      | (16.7)        |               |               |        |               |               |
| 1801–2700        | 208    | (38.7)        | 58           | (51.8)       | 6.31   | (2.77 to 14.40) | 5.88 (2.53 to 13.64) | 25     | (46.3) | 2.20 (0.93 to 5.23) | 1.65 (0.68 to 4.02) |
| >2700            | 150    | (27.9)        | 44           | (39.3)       | 6.28   | (2.70 to 14.63) | 6.02 (2.55 to 14.19) | 20     | (37.0) | 2.63 (1.09 to 6.37) | 2.09 (0.85 to 5.14) |
| **Systemic therapy** |        |               |               |               |        |               |               |               |        |               |               |
| Chemotherapy§**, euros |        |               |               |               |        |               |               |               |        |               |               |
| Median (P25-P75)  | 98.35  | (0.00–389.44) | 385.96 | (265.92–412.82) | 397.58 | (269.14–533.39) |               |               |        |               |               |
| None (0)¶        | 251    | (46.7)        | 7            | (6.3)        | 10     | (18.5)        |               |               |        |               |               |
| ≤400             | 164    | (30.5)        | 65           | (58.0)       | 18.74  | (7.22 to 48.66) | 27.65 (9.95 to 76.80) | 17     | (31.5) | 2.66 (1.08 to 6.53) | 2.16 (0.80 to 5.81) |
| >400             | 122    | (22.7)        | 40           | (35.7)       | 15.68  | (5.84 to 42.06) | 23.83 (8.06 to 70.52) | 27     | (50.0) | 5.27 (2.20 to 12.64) | 4.07 (1.47 to 11.29) |
| **Hormone therapy§**, euros |        |               |               |               |        |               |               |               |        |               |               |
| Median (P25-P75)  | 101.71 | (73.27–120.79) | 78.41 | (65.92–112.51) | 0.00   | (0.00–0.00)   |               |               |        |               |               |
| ≤80¶             | 177    | (33.0)        | 58           | (61.8)       | 0.43   | (0.24 to 0.76) | 0.41 (0.23 to 0.73) | 0      | (0.0)   | --               | --                 |
| 81–110           | 161    | (30.0)        | 22           | (19.6)       | 0.43   | (0.24 to 0.76) | 0.41 (0.23 to 0.73) | 0      | (0.0)   | --               | --                 |
| >110             | 199    | (37.1)        | 32           | (28.6)       | 0.52   | (0.32 to 0.85) | 0.52 (0.32 to 0.87) | 0      | (0.0)   | --               | --                 |
| **Targeted therapy§††**, euros |        |               |               |               |        |               |               |               |        |               |               |
| Median (P25-P75)  | 0.00   | (0.00–0.00)   | 25.00556     | (21.353.67–29.808.79) | 0.00   | (0.00–0.00)   |               |               |        |               |               |
| None (0)¶        | 537    | (100.0)       | 7            | (6.3)        | 54     | (100.00)      |               |               |        |               |               |
| ≤26000           | 0      | (0.0)         | 53           | (47.3)       | --     | --            | --             | 0      | (0.0)   | --               | --                 |
| >26000           | 0      | (0.0)         | 52           | (46.4)       | --     | --            | --             | 0      | (0.0)   | --               | --                 |
| **Day hospital§‡‡**, euros |        |               |               |               |        |               |               |               |        |               |               |

Table 3  Association between breast cancer classic subtype and healthcare costs, in euros, in the first 3 years following a breast cancer diagnosis in 2012
### Table 3 Continued

|                      | HR+/HER2- (N=537)   | HER2+ (N=112)     | TNBC (N=54)      |
|----------------------|---------------------|-------------------|------------------|
|                      | N (%)               | N (%)             |                  |
| **Median**           | 393.52 (0.00–590.28) | 2164.36 (2164.36–2262.74) | 590.28 (590.28–590.28) |
| **Radiotherapy**     |                     |                   |                  |
|                      | N (%)               | aOR (95% CI)*     | aOR (95% CI)†    |
| ≤600                 | 193 (35.9)          | 0.49 (0.05 to 4.52) | 0.72 (0.07 to 7.07) |
| >600                 | 116 (21.6)          | 246.48 (69.64 to 872.35) | 485.71 (123.60 to 1908.67) |
| **Other healthcare use** |                   |                   |                  |
|                      | N (%)               | aOR (95% CI)*     | aOR (95% CI)†    |
| **Hospitalisation**  |                     |                   |                  |
| ≤1450                | 176 (34.8)          | 2.63 (1.33 to 5.23) | 2.53 (1.26 to 5.07) |
| >1450                | 174 (32.4)          | 3.89 (1.98 to 7.63) | 3.50 (1.74 to 7.06) |
| **Genetic testing**  |                     |                   |                  |
| ≤1450                | 170 (33.9)          | 0.82 (0.47 to 1.41) | 0.65 (0.36 to 1.16) |
| >1450                | 164 (30.9)          | 1.36 (0.81 to 2.27) | 1.14 (0.67 to 1.93) |

Continued
Table 3  Continued

| HR+/HER2− (N=537) | HER2+ (N=112) | TNBC (N=54) |
|-------------------|---------------|-------------|
|                    | N (%)         | aOR (95% CI)* | N (%) | aOR (95% CI)* | N (%) | aOR (95% CI)* |
| None (0)¶         | 474 (88.3)    | 0.58 (0.18 to 1.90) | 45 (83.3) |
| ≤550              | 19 (3.5)      | 0.61 (0.26 to 1.43) | 2 (3.7) |
| >550              | 44 (8.2)      | 0.66 (0.27 to 1.56) | 7 (13.0) |

Other medical expenses§, euros

| Median (P25-P75) | N (%)         | aOR (95% CI)* | N (%) | aOR (95% CI)* | N (%) | aOR (95% CI)* |
|------------------|---------------|---------------|-------|---------------|-------|---------------|
| ≤350¶           | 180 (33.5)    | 0.61 (0.26 to 1.43) | 2 (1.8) |
| 351–900          | 176 (32.8)    | 37.46 (5.08 to 276.41) | 40 (35.7) |
| >900             | 181 (33.7)    | 60.09 (8.23 to 438.59) | 70 (62.5) |

Imaging§, euros

| Median (P25-P75) | N (%)         | aOR (95% CI)* | N (%) | aOR (95% CI)* | N (%) | aOR (95% CI)* |
|------------------|---------------|---------------|-------|---------------|-------|---------------|
| ≤450¶           | 192 (35.8)    | 2.05 (0.59 to 7.20) | 5 (4.5) |
| 451–750          | 165 (30.7)    | 2.60 (0.73 to 9.29) | 7 (6.3) |
| >750             | 180 (33.5)    | 24.94 (8.82 to 70.53) | 100 (89.3) |

Total cost§, euros

| Median (P25-P75) | N (%)         | aOR (95% CI)* | N (%) | aOR (95% CI)* | N (%) | aOR (95% CI)* |
|------------------|---------------|---------------|-------|---------------|-------|---------------|
| ≤8250¶          | 179 (33.3)    | 1.18 (0.16 to 8.55) | 3 (2.7) |
| 8251–12250       | 179 (33.3)    | 1.63 (0.22 to 12.12) | 2 (1.8) |
| >12 250          | 179 (33.3)    | 63.70 (14.88 to 272.80) | 107 (85.5) |
Table 3 Continued

|                | HR+/HER2− (N=537) | HER2+ (N=112) | TNBC (N=54) |
|----------------|-------------------|---------------|-------------|
| N (%)          | N (%)             | aOR (95% CI)* | N (%)       | aOR (95% CI)* | aOR (95% CI)* |
| The total may not add to 703 due to missing data. May not sum to 100% due to rounding. |

For items: surgeries, hormone therapy, appointments, hospitalisation, other medical expenses, imaging and total cost, the cut-offs used to define each category were determined as percentiles 33 and 66 of the respective cost among the HR+/HER2− subgroup. For items: chemotherapy, targeted therapy, day hospital, radiotherapy and genetic testing, categories were defined as none (0) and the median cost among the HR+/HER2− subgroup (among those who received the respective item) was used as the cut-off to define the other two categories.

*Adjusted for age (continuous) and education (≤4, 5–9, ≥10 years).
†Further adjusted for stage (I–III).
‡All surgeries/interventions, including breast surgeries and axillary surgeries. Imputed surgery cost for 87 patients who underwent surgery outside IPO-Porto.
§Variable dependent in the multinomial logistic regression model.
¶Category being used as the reference in the multinomial logistic regression model.
**Imputed chemotherapy cost for three patients who received chemotherapy outside IPO-Porto.
††Imputed targeted therapy cost for one patient who received targeted therapy outside IPO-Porto.
‡‡Day hospital sessions include the administration of intravenous, subcutaneous and/or intramuscular therapy (ie, chemotherapy, trastuzumab, goserelin and fulvestrant).
§§The cost of brachytherapy for the seven patients who only received brachytherapy (and no external radiotherapy) is included in hospitalisation costs and not in radiotherapy costs.
¶¶Other medical expenses include laboratory and pathology tests, and blood transfusions.

aOR, adjusted OR; HR, hormone receptors; IPO-Porto, Portuguese Institute of Oncology of Porto; TNBC, triple negative breast cancer.
From 2012 until now, there have been major advances in loco-regional and in systemic therapy for early breast cancer. The cost of radiotherapy may have decreased due to the adoption of hypofractionated regimens and of accelerated partial-breast irradiation (to selected patients), which decreases the number of radiotherapy sessions needed and, therefore, reduces both direct and indirect costs.

Among patients with HER2+ breast cancer, the introduction of trastuzumab biosimilar drugs and of a subcutaneous trastuzumab formulation lowered the price of this adjuvant therapy. Additionally, the Persephone trial showed that 6-month therapy with trastuzumab is non-inferior to the standard 12-month regimen. Nonetheless, the 6-month regimen has not been widely adopted, due to the negative results of other non-inferiority trials and due to concerns regarding its efficacy among higher-risk groups. Hence, 12 months of adjuvant trastuzumab continues to be considered the standard-of-care in developed countries. On the other hand, since 2013, three more anti-HER2 drugs were approved in the (neo)adjuvant setting: pertuzumab, neratinib and T-DM1. As an example, in our cohort, 60% of patients with HER2+ tumours had stage II/III and would currently be proposed to neoadjuvant chemotherapy plus trastuzumab/pertuzumab. As four cycles of pertuzumab have a direct cost of €13,978, this means that the overall median cost per patient could have increased by 20% among this subgroup. However, these drugs also decrease the likelihood of disease relapse, thus potentially reducing expenditures related to the treatment of breast cancer recurrence.

On the other hand, around half of the patients with HR+/HER2− tumours in our cohort received chemotherapy. Nowadays, a part of these patients could have their tumours tested with a genomic signature (eg, PAM50, oncotype, Mammaprint) in order to avoid chemotherapy, which would decrease both direct and indirect costs. However, after the publication of the SOFT/TEXT trials, many premenopausal women with HR+ tumours started receiving adjuvant tamoxifen or exemestane plus ovarian suppression for 5years, which have potentially increased the cost of their treatment. Therefore, patients’ menopausal status should be taken into account in future analyses of the cost of breast cancer care. In addition, there are large ongoing randomised clinical trials, testing two to 3 years of adjuvant treatment with CDK4/6 inhibitors in patients with HR+/HER2− breast cancer (monarchE; NATALEE, NCT03701334), which may significantly increase the cost of treatment for this subgroup of patients. For example, the total cost of 2 years of therapy with abemaciclib (tested in the monarchE trial) is almost €100,000/patient, only considering the cost of the drug and not taking into account all the other direct (laboratory tests, medical appointments, etc) and indirect expenses associated with the treatment. Likewise, in early TNBC, treatment costs may significantly escalate in the future due to the possible introduction of new immunotherapy drugs or poly-ADP ribose polymerase (PARP) inhibitors (OlympiA trial, NCT02032823).
Therefore, due to the increase in the number of available systemic therapy options, namely of targeted drugs, there is a growing concern regarding the ‘financial toxicity’ of treating breast cancer due to the escalation of costs. This concern exists not only in the metastatic setting, but increasingly in the early setting as well. 42 43 The European Society for Medical Oncology developed the ‘Magnitude of Clinical Benefit Scale’, which aims to objectively evaluate the clinical benefit of each approved systemic drug, taking into account the drug’s survival benefit, associated toxicity and impact on quality of life. 44 These evaluations, coupled with real-cost assessments such as the one presented in this study, may help inform stakeholders on reimbursement options for the many drugs that are currently being tested and regarding other cancer care policies.

CONCLUSION
In this patient-level data analysis, the cost of early breast cancer care within the first 3 years following diagnosis was mainly driven by the breast cancer subtype and, to a lesser extent, by stage at diagnosis. Among patients with HER2+ breast cancer, the median overall cost of care was fourfold higher compared with those with HR+/HER2− and TNBC, and this difference was mostly related to the cost of systemic therapy, including trastuzumab. These data provide important information for the design of future economic studies, including the evaluation of innovative drugs, as it accurately quantified the use and cost associated with each of the different components of early breast cancer care. Moreover, these findings highlight the preponderance that targeted systemic therapy might have in the overall cost of care for patients with early breast cancer.

Author affiliations
1EPIUnit, Universidade do Porto Instituto de Saúde Pública, Porto, Portugal
2Medical Oncology Department, Instituto Português de Oncologia do Porto Francisco Gentil EPE, Porto, Portugal
3Academic Trials Support Unit, Instituto Jules Bordet, Brussels, Belgium
4Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Universidade do Porto Faculdade de Medicina, Porto, Portugal
5Surgical Oncology Department, Instituto Português de Oncologia do Porto Francisco Gentil EPE, Porto, Portugal
6Escola Nacional de Saúde Pública, Universidade Nova de Lisboa, Lisboa, Portugal
7Neurology Department, Instituto Português de Oncologia do Porto Francisco Gentil EPE, Porto, Portugal

Twitter Mariana Brandão @MarianaBrandao0 and Samantha Morais @samanthamorais

Acknowledgements We thank Dr João Dias, from IPO-Porto, for helping with the collection of stage information for some of the included patients.

Funding This study was funded by the European Regional Development Fund (FEDER) through the Operational Programme Competitiveness and Internationalisation and national funding from the Foundation for Science and Technology – FCT (Portuguese Ministry of Science, Technology and Higher Education), under the project ‘A 5-year prospective cohort study on the neurological complications of breast cancer: frequency and impact in patient-reported outcomes’ (POCI-01-0145-FEDER-016867, Ref. PTDC-DTP/EPI/7183/2014), and national funding from FCT, under the Unidade de Investigação em Epidemiologia – Instituto de Saúde Pública da Universidade do Porto (EPIUnit) (UIDB/04750/2020). SM and LL-C were also funded under the scope of the project ‘NEON-PC’.

- Neuro-oncological complications of prostate cancer: longitudinal study of cognitive decline’ (POCI-01-0145-FEDER-032358; ref. PTDC-SAII-EPI/32358/2017). An individual grant attributed to NA (SFRH/BD/119390/2016) was cofunded by FCT and the ‘Programa Operacional Capital Humano’ (POCH/FSE). Data management activities up to the first year of follow-up were supported by the Chair on Pain Medicine of the Faculty of Medicine, University of Porto and by the Grünenthal Foundation—Portugal.

Competing interests MB has received a travel grant and speaker honorarium, unrelated to this study, from Roche/GNE, and the Institut Jules Bordet has received research grants, unrelated to this study, from Roche/GNE, Radius, AstraZeneca, Lilly, MSD, GSJ/Novartis, Synthion, Servier and Pfizer. IP has participated in advisory boards, unrelated to this study, from Roche, AstraZeneca, Pfizer, Yansen and Novartis. MBdO has received travel grants, unrelated to this study, from Roche and Janssen.

Patient consent for publication Not required.

Ethics approval All procedures performed in the present study were in accordance with the ethical standards of the institutional Ethics Committee of the Portuguese Institute of Oncology of Porto (ref. CES 406/011, CES 99/014 and CES 290/014) and the national research committee (Portuguese Data Protection Authority, ref. 9469/2012 and 8601/2014), and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The datasets generated and analysed during the current study are not publicly available given that the included patients did not specifically provide their consent for public sharing of their data and that anonymisation, even if possible, is partially impaired by the fact that patients were treated in the same institution and diagnosed in the same year, with some of the groups being small. Nonetheless, data are available from the corresponding author on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iDs
Mariana Brandão http://orcid.org/0000-0002-1653-3544
Samantha Morais http://orcid.org/0000-0001-5808-0179
Luísa Lopes-Conceição http://orcid.org/0000-0002-5064-9911
Filipa Fontes http://orcid.org/0000-0001-9246-588X
Natália Araújo http://orcid.org/0000-0002-1652-8999
Marina Borges http://orcid.org/0000-0002-8073-6506
Susana Pereira http://orcid.org/0000-0002-0593-262X
Nuno Lunet http://orcid.org/0000-0003-1870-1430

REFERENCES
1 Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2 Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of who mortality database. BMJ 2010;341:c3620.
3 Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers 2019;5:1–31.
4 Sun L, Legood R, Dos-Santos-Silva I, et al. Global treatment costs of breast cancer by stage: a systematic review. PLoS One 2018;13:e0207993.
5 Sotiriou C, Puszta L. Gene-Expression signatures in breast cancer. N Engl J Med 2009;360:790–800.
6 Burstein HJ, Curigiano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. *Ann Oncol* 2019;30:1541–57.

7 Seferina SC, Ramaekers BLT, de Boer M, et al. Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: a study of the Southeast Netherlands breast cancer Consortium. *Oncotarget* 2017;8:79223–33.

8 Kerr DJ, Jani A, Gray SM. Strategies for sustainable cancer care. *Am Soc Clin Oncol Educ Book* 2016;35:e11–15.

9 Lungo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. *Lancet Oncol* 2013;14:1165–74.

10 Campbell JD, Ramsey SD. The costs of treating breast cancer in the U.S. *PharmacoEconomics* 2009;27:199–209.

11 Hoang Lan N, Laohasiriwong W, Stewart JF, et al. Cost of treatment for breast cancer in central Vietnam. *Glob Health Action* 2013;6:18872.

12 Meneses-Garcia A, Ramirez T, Ruiz-Godoy L, et al. Costs of breast cancer treatment prior to the introduction of Immune-based therapy in Mexico. *Rev Med Inst Mex Seguro Soc* 2012;50:10–24.

13 Davari M, Yazdanpanah F, Aslani A, et al. The direct medical costs of breast cancer in Iran: analyzing the patient’s level data from a cancer specific hospital in Isfahan. *Int J Prev Med* 2013;4:748–54.

14 Tekin RN, Saric M. Determining breast cancer treatment costs using the top down cost approach. *Eur J Breast Health* 2019;15:242–8.

15 Breast Clinic, IPO-PORTO. Available: https://www.ipporto.pt/en/clinicamama/ [Accessed 18 Oct 2019].

16 Candalos F, Kulis S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2019;30:1194–220.

17 Pereira S, Fontes F, Sonin T, et al. Neurological complications of breast cancer: study protocol of a prospective cohort study. *BMJ Open* 2014;4:e006501.

18 Nouws S, Brandão M, Fontes F, et al. Factors associated with time to breast cancer diagnosis and treatment in unscreened women in Portugal. *Woman Health* 2019;59:1–14.

19 Miró S, Costa L, Llorente L, et al. Treatment and other healthcare use of breast cancer patients with a previous cancer diagnosis. *Anticancer Res* 2020;40:1041–8.

20 Lopes-Conceição L, Brandão M, Araújo N, et al. Quality of life trajectories during the first three years after diagnosis of breast cancer: the NEON-SC study. *J Public Health* 2019;22. doi:10.1093/pubmed/fdz159. [Epub ahead of print: 27 Dec 2019].

21 Edge S, Byrd D, Compton C, et al. *AJCC cancer staging manual*. 7th ed. New York: Springer, 2010.

22 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer experience from a large study with long-term follow-up. *Histopathology* 1991;19:403–10.

23 Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of clinical Oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol* 2007;25:118–45.

24 Hammond MEH, Hayes DF, Dowsett M, et al. American Society of clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol* 2010;28:2784–95.

25 Dowsett M, Nielsen TO, A’Hern R, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International KI67 in breast cancer Working group. *J Nat Cancer Inst* 2011;103:1656–64.

26 Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy for Breast Cancer 2011. *Ann Oncol* 2011;22:1736–47.

27 Portaia 234/2015, 2015-08-07. Diario Repúb. Eletrônico, 2015. Available: https://cnes.dpiapis/pt/search/00968713/details/maximized [Accessed 2 Feb 2020].

28 Harfouche A, Silva S, Faria J, et al. [Breast Cancer: Value-Based Healthcare, Costs and Financing]. *Acta Med Port* 2019;32:762–8.

29 Capri S, Russo A. Cost of breast cancer based on real-world data: a cancer registry study in Italy. *BMC Health Serv Res* 2017;17:84.

30 Laas E, Vatale A-L, Aballea S, et al. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. *J Med Econ* 2012;15:1167–75.

31 Wolstenholme JL, Smith SJ, Whynes DK. The costs of treating breast cancer in the United Kingdom: implications for screening. *Int J Technol Assess Health Care* 1998;14:277–89.

32 Smith BD, Bellon JR, Blitzzrau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for radiation oncology (ASTRO) evidence-based guideline. *Pract Radiat Oncol* 2018;8:145–52.

33 Correa C, Harris EE, Leonard MC, et al. Accelerated partial breast irradiation: Executive summary for the update of an ASTRO evidence-based consensus statement. *Pract Radiat Oncol* 2017;7:73–9.

34 Barbier L, Declerck P, Simoens S, et al. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. *Br J Cancer* 2019;120:440–9.

35 Hedayati E, Fracheboud L, Srikant V, et al. Economic benefits of subcutaneous trastuzumab administration: a single institutional study from Karolinska university hospital in Sweden. *PloS One* 2019;14:e021783.

36 Earl HM, Hiller L, Vallier A-L, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (Persephone): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. *Lancet* 2019;393:259–62.

37 Brande N, Gelber RD, Persson E. are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? *NPJ Breast Cancer* 2019;5:1–4.

38 Borges A, Pereira F, Redondo P, et al. PCN204 COST-ESTIMATE of adding neoadjuvant pertuzumab for the treatment of HER2+ breast cancer in an institution in Portugal. *Value Health* 2019;22:S475.

39 Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. *N Engl J Med* 2018;379:122–37.

40 Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). *Journal of Clinical Oncology* 2020;JCO.20.02514.

41 Schmid P, Cortes J, Puustal L, et al. Pembrolizumab for early triple-negative breast cancer. *N Engl J Med* 2020;382:910–21.

42 Semin JW, Palm D, Smith LM, et al. Understanding breast cancer survivors’ financial burden and distress after financial assistance. *Support Care Cancer* 2020;28:4241–8.

43 Chino F, Peppercorn JM, Rushing C, et al. Out-Of-Pocket costs, financial distress, and underinsurance in cancer care. *JAMA Oncol* 2017;3:1582–4.

44 Cherry N, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS). *Ann Oncol* 2015;26:1547–73.